Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
14 mai 2024 08h00 HE
|
Daré Bioscience, Inc.
Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the...
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
07 mai 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
02 mai 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub, a...
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
30 avr. 2024 07h30 HE
|
Daré Bioscience, Inc.
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments...
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
23 avr. 2024 08h00 HE
|
Daré Bioscience, Inc.
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
11 avr. 2024 08h00 HE
|
Daré Bioscience, Inc.
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
28 mars 2024 08h00 HE
|
Daré Bioscience, Inc.
2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement...
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
21 mars 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
22 févr. 2024 08h00 HE
|
Daré Bioscience, Inc.
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual...
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
31 janv. 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST),...